natgillin/translations-raw huggingface dataset:
Ritonavir binds to both human alpha 1-acid glycoprotein (AAG) and human serum albumin (HSA) with comparable affinities.
Ritonavir se i na alfa1-kiseli glikoprotein (alpha 1-acid glycoprotein, AAG) i na ljudski serumski albumin (human serum albumin, HSA) veže usporedivim afinitetom.
Ritonavir C12  0.86
Ritonavir C12 ↔ 0,86
Ritonavir C12: ↓ 0.74
Ritonavir C12  0,74
Ritonavir C12: ↔ 0.86
Ritonavir C12:  0,86
Ritonavir Cmax and AUCτ ↔ Voriconazole Cmax  66% Voriconazole AUCτ  82%
Ritonavir Cmax and AUC ↔ Vorikonazol Cmax  66% Vorikonazol AUC  82
Ritonavir Cmax ↔ 0.93 (0.78-1.07)
Ritonavir Cmax  0,93 (0,78-1,07)
Ritonavir Cmax  0.93 (0.78-1.07)
Ritonavir Cmax  0,93 (0,78-1,07)
Ritonavir Cmax  0.61
Ritonavir Cmax  0,61
Ritonavir Cmax  25% Ritonavir AUCτ  13% Voriconazole Cmax  24% Voriconazole AUCτ  39%
Ritonavir Cmax  25% Ritonavir AUC 13% Vorikonazol Cmax  24% Vorikonazol AUC  39
Ritonavir Cmax  25% Ritonavir AUC 13% Voriconazole Cmax  24% Voriconazole AUC  39%
Ritonavir Cmax  25% Ritonavir AUC 13
Ritonavir Cmax: ↓ 0.61
Ritonavir Cmax:  0,61
Ritonavir Cmax: ↔ 1.02
Ritonavir Cmax 1,02
Ritonavir Cmin ↔ 0.93 (0.76-1.14)
Ritonavir Cmin  0,93 (0,76-1,14)
Ritonavir Cmin  0.93 (0.76-1.14)
Ritonavir Cmin  0,93 (0,76-1,14)
Ritonavir Cmin: 39 %
Cmin ritonavira: 39
Ritonavir concentrations in this study were highly variable and somewhat lower than those obtained in adults receiving 600 mg (approximately 330 mg/m²) twice daily.
Koncentracije ritonavira u tom su istraživanju bile vrlo varijabilne i nešto niže od onih izmjerenih u odraslih koji su primali 600 mg (oko 330 mg/m2) dva puta na dan.
Ritonavir dose in Viekirax will provide atazanavir pharmacokinetic enhancement).
ritonavira, u kombinaciji s
Ritonavir Dose once daily (mg)
Ritonavir doza* jedanput na dan (mg)
Ritonavir dosed as an antiretroviral agent
Ritonavir doziran ako antiretrovirusni lijek
Ritonavir dosed as an antiretroviral agent Adults
Ritonavir doziran kao antiretrovirusni lijek Odrasli
Ritonavir film-coated tablets are administered orally and should be ingested with food (see section 5.2).
Ritonavir filmom obložene tablete primjenjuju se oralno i preporučuje se uzimanje s hranom (vidjeti dio 5.2).
Ritonavir increases the serum levels of maraviroc as a result of CYP3A inhibition.
Ritonavir povisuje serumske razine maraviroka zbog inhibicije CYP3A.
Ritonavir inhibits the transporters P-glycoprotein, OATP1B1 and OATP1B3, and co-administration with substrates of these transporters can result in increased plasma concentrations of these compounds (e.g. dabigatran etexilate, digoxin, statins and bosentan; see the Interaction table below).
Ritonavir inhibira transportere P-glikoprotein, OATP1B1 i OATP1B3 te istodobna primjena sa supstratima ovh transportera može rezultirati povećanjem koncentracije ovih lijekova u plazmi (npr. dabigatran eteksilat, digoksin, statini i bosentan; vidjeti tablicu interakcija ispod).
Ritonavir is a CYP3A inhibitor that increases the systemic exposure of the CYP3A substrate paritaprevir.
Ritonavir je inhibitor CYP3A koji povećava sistemsku izloženost CYP3A substratu paritapreviru.
Ritonavir is a potent inhibitor of
Ritonavir je snažan inhibitor
Ritonavir is administered immediately following REYATAZ powder administration.
Ritonavir se primjenjuje odmah nakon primjene REYATAZ praška.
Ritonavir is another protease inhibitor that is used as a ‘booster’.
Ritonavir je drugi inhibitor proteaze koji se koristi kao „booster”.
Ritonavir is another protease inhibitor that is used as a ‘booster’.
Ritonavir je drugi inhibitor proteaze koji se koristi kao „pojačivač”.
ritonavir is contraindicated with
kontraindicirana s triazolamom.
Ritonavir is not active against HCV.
Ritonavir ne djeluje na HCV.
Ritonavir is predominantly metabolised by CYP3A and to a lesser extent, by CYP2D6.
Ritonavir se najvećim dijelom metabolizira posredstvom CYP3A, a u manjoj mjeri posredstvom CYP2D6.
Ritonavir may decrease plasma concentrations of voriconazole. (induction of CYP450 enzymes by ritonavir)
Ritonavir može sniziti koncentracije vorikonazola u plazmi. (indukcija CYP450 enzima ritonavirom)
Ritonavir may decrease plasma concentrations of voriconazole. (induction of CYP450 enzymes)
Ritonavir može sniziti koncentracije vorikonazola u plazmi. (indukcija CYP450 enzima)
Ritonavir may increase
Ritonavir može inducirati glukuronidaciju metadona.
ritonavir once daily dose
Doza ritonavira jedanput na dan
Ritonavir oral solution also contains propylene glycol (26.0% v/v).
Ritonavir oralna otopina sadrži propilenglikol (26,0% v/v).
Ritonavir oral solution also contains the azo-colouring agent sunset yellow (E110) which may cause allergic reactions.
Ritonavir oralna otopina također sadrži azo-boja sunset yellow (E110) koje može uzrokovati alergijske reakcije.
Ritonavir oral solution contains alcohol (43 % v/v), ie up to 2572.5 mg per maximum dose of 600 mg, equivalent to 81 ml beer (4%), 23 ml wine (14%) per dose.
Ritonavir oralna otopina sadrži alkohol (43 % v/v), tj. do 2572,5 mg po maksimalnoj dozi od 600 mg, što odgovara 81 ml piva (4%), 23 ml vina (14%) po dozi.
Ritonavir oral solution contains castor oil polyoxyl which may cause stomach upset and diarrhoea.
Ritonavir oralna otopina sadrži ricinusovo ulje polioksil koje može uzrokovati želučane tegobe i proljev.
Ritonavir oral solution should not be co- administered with amprenavir oral solution to children due to the risk of toxicity from excipients in the two formulations.
U djece se ritonavir oralna otopina ne smije primjenjivati istodobno s amprenavir oralnom otopinom zbog rizika od toksičnosti izazvane pomoćnim tvarima u tim pripravcima.
Ritonavir pharmacokinetic parameters were not statistically significantly associated with body weight or lean body mass.
Pokazatelji farmakokinetike ritonavira nisu se statistički značajno razlikovali s obzirom na tjelesnu težinu ni na masu tijela bez masti.
Ritonavir plasma concentrations increased when renal function was reduced: Cmax and AUC values were 26% to 42% higher, 48% to 80% higher and 66% to 114% higher in subjects with mild, moderate and severe renal impairment, respectively.
Koncentracija ritonavira u plazmi se povećala pri smanjenoj bubrežnoj funkciji: vrijednosti Cmax i AUC bile su od 26% do 42% veće u ispitanika s blagim oštećenjem, od 48% do 80% veće u ispitanika s umjerenim oštećenjem i od 66% do 114% veće u ispitanika s teškim oštećenjem bubrežne funkcije.
Ritonavir plasma exposures in patients 50 – 70 years of age when dosed 100 mg in combination with lopinavir or at higher doses in the absence of other protease inhibitors is similar to that observed in younger adults.
Izloženost ritonaviru iz plazme u bolesnika 50 – 70 godina starosti, pri primjeni 100 mg ritonavira u kombinaciji s lopinavirom, ili u većim dozama ali bez drugog inhibitora proteaza, slična je onoj u mlađih bolesnika.
ritonavir row below.
Vidjeti i navode za ritonavir, niže u
ritonavir was used with or without enfuvirtide, it has been observed that the steady-state plasma tipranavir trough concentration of patients receiving enfuvirtide were 45% higher as compared to patients not receiving enfuvirtide.
U ispitivanjima u kojima je tipranavir s niskom dozom ritonavira rabljen sa ili bez enfuvirtida, primijećeno je da su koncentracije tipranavira na kraju dozirnog intervala u stanju dinamičke ravnoteže bile 45% više u bolesnika koji su primali enfuvirtid.
Ritonavir 
Interakcija
Ritonavir  (effectiveness as boosting agent not modified).
Ritonavir  (nije promijenjena djelotvornost ritonavira kao pojačivača)
ritonavir, and oral midazolam is
midazolama je kontraindicirana
Ritonavir, atazanavir, saquinavir, darunavir, indinavir, nelfinavir
Ritonavir, atazanavir, sakvinavir, darunavir, indinavir, nelfinavir
ritonavir, cobicistat, lopinavir, delavirdine, amprenavir, fosamprenavir
ritonavir, kobicistat, lopinavir, delavirdin, amprenavir, fosamprenavir
ritonavir, does not cause any
glukokortikoida se ne preporuča,
Ritonavir, ketoconazole (except in shampoo), itraconazole, erythromycin, nelfinavir, saquinavir - used to treat different kinds of infections.
Ritonavir, ketokonazol (osim u obliku šampona), itrakonazol, eritromicin, nelfinavir, sakvinavir - primjenjuju se za liječenje različitih vrsta infekcija.
ritonavir, with abacavir is not
abakavira se ne preporučuje, osim
ritonavir, with alfuzosin is contraindicated.
Istodobna primjena Aptivusa s niskom dozom ritonavira i alfuzosina je kontraindicirana.
ritonavir, with amiodarone, bepridil
dozom ritonavira povećava
ritonavir, with astemizole or
astemizola ili terfenadina je
ritonavir, with atazanavir/ritonavir
atazanavira/ritonavira se ne
ritonavir, with dihydroergotamine,
dihidroergotamina,
ritonavir, with flecainide,
niskom dozom ritonavira i
ritonavir, with lopinavir/ritonavir is
lopinavira/ritonavira se ne
ritonavir, with pimozide, sertindole,
pimozida, sertindola, ili kvetiapina
ritonavir, with proton pump
inhibitora protonske pumpe se ne
ritonavir, with saquinavir/ritonavir is not recommended.
sakvinavira/ritonavira se ne preporučuje.
Ritonavir- boosted Invirase at a dose of 2000 mg once daily with ritonavir 100 mg once daily has not been studied with regard to the risk of QT prolongation and is not recommended.
Nije ispitivan utjecaj doze lijeka Invirase od 2000 mg jednom na dan, pojačanog ritonavirom u dozi od 100 mg jednom na dan, na rizik produljenja QT-intervala te se ta doza ne preporučuje.
ritonavir-boosted protease inhibitors (with the exception of tipranavir/ritonavir),
inhibitori proteaza pojačani ritonavirom (osim tipranavira/ritonavira),
ritonavir.
Antikoagulansi
ritonavir.
povećava razine
ritonavir.
ritonavira.
ritonavir.
ritonavirom
ritonavir.
ritonavirom.
ritonavir/
CYP3A4/P
Ritonavir/efavirenz (500 mg twice daily/600 mg once daily)
(500 mg dvaput na dan/600 mg
ritonavir/ombi
inhibiraju
Ritonavir/Tenofovir disoproxil fumarate
ritonavir/tenofovirdizoproksil fumarat
Ritonavir100 mg twice daily with saquinavir 1000 mg twice daily provides saquinavir systemic exposure over 24 hours similar to or greater than those achieved with saquinavir 1200 mg three times daily without ritonavir.
Ritonavir 100 mg dva puta na dan sa sakvinavirom 1000 mg dva puta na dan osigurava sistemnu izloženost sakvinaviru tijekom 24 sata sličnu ili veću od one koja se postiže sakvinavirom u dozi od 1200 mg triput na dan bez ritonavira.
Ritonavir:
boceprevir:
Ritonavir:
GS-3310072:
Ritonavir: AUC  45%*
Ritonavir: AUC 45
Ritonavir: Cmax  63%*
Ritonavir: Cmax 63
Rituximab + chlorambucil
rituksimab + klorambucil
Rituximab intravenous formulation
Rituksimab intravenska formulacija
rituximab or other murine-derived proteins if you are pregnant or breast-feeding (see also section “pregnancy and breast feeding”).
rituksimab ili druge proteine dobivene iz miševa ako ste trudni ili dojite (pogledajte i dio "Trudnoća i dojenje").
Rituximab pharmacokinetics following single dose administration of MabThera subcutaneous 375 mg/ m2, 625 mg/ m2 and 800 mg/ m2 were compared with MabThera intravenous 375 mg/ m2 in FL patients.
Farmakokinetika rituksimaba nakon primjene jedne doze lijeka MabThera za supkutanu primjenu od 375 mg/m2, 625 mg/m2 i 800 mg/m2 uspoređena je s onom nakon primjene lijeka MabThera za intravensku primjenu u dozi od 375 mg/m2 u bolesnika s FL-om.
Rituximab pretreatment is necessary to clear circulating B-cells, enabling ibritumomab tiuxetan [90Y] to deliver radiation more specifically to the lymphoma B-cells.
Prethodno liječenje rituksimabom nužno je radi uklanjanja cirkulirajućih B-stanica, što ibritumomab tiuksetanu [90Y] omogućuje specifičnije zračenje B-stanica limfoma.
Rituximab subcutaneous formulation
Rituksimab supkutana formulacija
Rituximab was administered at a dose of 375 mg/m2 in the first cycle, Day 1, and 500 mg/m2 Cycles 2 through 6, Day 1.
Rituksimab je bio primijenjen u dozi od 375 mg/m2 1. dana u prvom ciklusu i 500 mg/m2 1. dana u 2.-6. ciklusu.
Rituximab was detectable in the serum of patients 3 – 6 months after completion of last treatment.
Rituksimab je bilo moguće otkriti u serumu bolesnika 3 – 6 mjeseci nakon završetka liječenja.
Rivaroxaban 10 mg od
rivaroksaban 10 mg jedanput na dan
Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily
Rivaroksaban 15 mg dvaput na dan kroz 3 tjedna, te potom 20 mg jedanput na dan
Rivaroxaban 2.5 mg and 10 mg tablets can be taken with or without food.
Rivaroksaban 2,5 mg i 10 mg tableta može se uzimati s hranom ili bez nje.
rivaroxaban apixaban
rivaroksaban apiksaban
rivaroxaban exposure which may
izloženost rivaroksabanu što može
Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2).
Rivaroksaban ima poluvrijeme eliminacije od približno 5 do 13 sati (vidjeti dio 5.2.).
Rivaroxaban has not been studied in interventional clinical trials in patients undergoing hip fracture surgery to evaluate efficacy and safety.
Nisu provedena intervencijska klinička ispitivanja s rivaroksabanom u bolesnika podvrgnutih kirurškom zahvatu zbog prijeloma kuka, kojima bi se procijenila djelotvornost i sigurnost lijeka.
Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability.
Rivaroxaban je visokoselektivni, direktni inhibitor faktora Xa, bioraspoloživ nakon peroralne primjene.
Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms.
Rivaroksaban se metabolizira s pomoću CYP3A4, CYP2J2 i mehanizmima neovisnima o CYP- izoformama.
Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily.
Farmakokinetika rivaroksabana približno je linearna do doze od 15 mg jedanput na dan.
Rivaroxaban:
lopinavirom/ritonavirom.
Rivaroxaban:
Rivaroksaban
Rivastigmine
<0,0011
Rivastigmine
ADAS-Cog
Rivastigmine
Health
Rivastigmine
in 3M
Rivastigmine
Populacija/Posjet
Rivastigmine 1 A Pharma 1.5 mg [folding box only]
Rivastigmin 1 A Pharma 1,5 mg [samo kutija]
Rivastigmine 1 A Pharma 1.5 mg hard capsules Rivastigmine
Rivastigmin 1 A Pharma 1,5 mg tvrde kapsule rivastigmin
Rivastigmine 1 A Pharma 1.5 mg hard capsules Rivastigmine 1 A Pharma 3 mg hard capsules Rivastigmine 1 A Pharma 4.5 mg hard capsules Rivastigmine 1 A Pharma 6 mg hard capsules
Rivastigmin 1 A Pharma 1,5 mg tvrde kapsule Rivastigmin 1 A Pharma 3 mg tvrde kapsule Rivastigmin 1 A Pharma 4,5 mg tvrde kapsule Rivastigmin 1 A Pharma 6 mg tvrde kapsule
Rivastigmine 1 A Pharma 1.5 mg hard capsules Rivastigmine 1 A Pharma 3 mg hard capsules Rivastigmine 1 A Pharma 4.5 mg hard capsules Rivastigmine 1 A Pharma 6 mg hard capsules Rivastigmine
Rivastigmin 1 A Pharma 1,5 mg tvrde kapsule Rivastigmin 1 A Pharma 3 mg tvrde kapsule Rivastigmin 1 A Pharma 4,5 mg tvrde kapsule Rivastigmin 1 A Pharma 6 mg tvrde kapsule rivastigmin
Rivastigmine 1 A Pharma 1.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a yellow cap and yellow body, with a red imprint “RIV 1.5 mg” on the body.
Rivastigmin 1 A Pharma 1,5 mg tvrde kapsule, koje sadrže bjelkasti do žućkasti prašak, imaju žutu kapicu i žuto tijelo s crvenom oznakom „RIV 1,5 mg“.
Rivastigmine 1 A Pharma 1.5 mg hard capsules: Capsule shell:
Rivastigmin 1 A Pharma 1,5 mg tvrde kapsule: Ovojnica kapsule:
Rivastigmine 1 A Pharma 2 mg/ml [folding box only]
Rivastigmin 1 A Pharma 2 mg/ml [samo kutija]
Rivastigmine 1 A Pharma 2 mg/ml oral solution Rivastigmine
Rivastigmin 1 A Pharma 2 mg/ml oralna otopina rivastigmin
Rivastigmine 1 A Pharma 3 mg [folding box only]
Rivastigmin 1 A Pharma 3 mg [samo kutija]
Rivastigmine 1 A Pharma 3 mg and 6 mg hard capsules: Capsule shell:
Rivastigmin 1 A Pharma 3 mg i 6 mg tvrde kapsule: Ovojnica kapsule:
Rivastigmine 1 A Pharma 3 mg hard capsules Rivastigmine
Rivastigmin 1 A Pharma 3 mg tvrde kapsule rivastigmin
Rivastigmine 1 A Pharma 3 mg hard capsules, which contain an off-white to slightly yellow powder, have an orange cap and orange body, with a red imprint “RIV 3 mg” on the body.
Rivastigmin 1 A Pharma 3 mg tvrde kapsule , koje sadrže bjelkasti do žućkasti prašak, imaju narančastu kapicu i narančasto tijelo s crvenom oznakom „RIV 3 mg“.
Rivastigmine 1 A Pharma 4.5 mg [folding box only]
Rivastigmin 1 A Pharma 4,5 mg [samo kutija]
Rivastigmine 1 A Pharma 4.5 mg hard capsules Rivastigmine
Rivastigmin 1 A Pharma 4,5 mg tvrde kapsule rivastigmin
Rivastigmine 1 A Pharma 4.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and red body, with a white imprint “RIV 4.5 mg” on the body.
Rivastigmin 1 A Pharma 4,5 mg tvrde kapsule, koje sadrže bjelkasti do žućkasti prašak, imaju crvenu kapicu i crveno tijelo s bijelom oznakom „RIV 4,5 mg“.
Rivastigmine 1 A Pharma 6 mg hard capsules Rivastigmine
Rivastigmin 1 A Pharma 6 mg tvrde kapsule rivastigmin
Rivastigmine 1 A Pharma 6 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and orange body, with a red imprint “RIV 6 mg” on the body.
Rivastigmin 1 A Pharma 6 mg tvrde kapsule, koje sadrže bjelkasti do žućkasti prašak, imaju crvenu kapicu i narančasto tijelo s crvenom oznakom „RIV 6 mg“.
Rivastigmine 1 A Pharma 6 mg[folding box only]
Rivastigmin 1 A Pharma 6 mg [samo kutija]
Rivastigmine 1 A Pharma is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Rivastigmin 1 A Pharma se primjenjuje za liječenje odraslih bolesnika s blago do umjereno teškom Alzheimerovom demencijom, progresivnim poremećajem mozga koji postupno utječe na pamćenje, intelektualnu sposobnost i ponašanje.
Rivastigmine 1 A Pharma is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Rivastigmin 1A Pharma se primjenjuje za liječenje odraslih bolesnika s blago do umjereno teškom Alzheimerovom demencijom, progresivnim poremećajem mozga koji postupno utječe na pamćenje, intelektualnu sposobnost i ponašanje.
Rivastigmine 1 A Pharma might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson’s disease or to prevent travel sickness).
Rivastigmin 1 A Pharma može utjecati na antikolinergičke lijekove (lijekove koji se koriste za ublažavanje grčeva ili spazama u želucu, za liječenje Parkinsonove bolesti ili za sprečavanje mučnine na putovanju).
Rivastigmine 1 A Pharma oral solution is supplied as 50 ml or 120 ml of a clear, yellow solution (2.0 mg/ml base) in an amber glass bottle with a child-resistant cap, foam liner, dip tube and self aligning plug.
Oralna otopina Rivastigmin 1 A Pharma isporučuje se kao bistra, žuta otopina od 50 ml ili 120 ml (2 mg/ml baze) u smeđoj staklenoj bočici sa sigurnosnim zatvaračem za djecu, pjenastom oblogom, umetnutom cjevčicom i čepom utisnutim u grlo bočice.
Rivastigmine 1 A Pharma oral solution should be used within 1 month of opening the bottle.
Oralnu otopinu Rivastigmin 1 A Pharma treba upotrijebiti u roku od 1 mjesec od otvaranja bočice.
Rivastigmine 1 A Pharma should not be used during pregnancy unless clearly necessary.
Rivastigmin 1 A Pharma ne smije se primjenjivati tijekom trudnoće, osim ako to nije nužno potrebno.
Rivastigmine 13.3 mg/24 h*
Rivastigmin 13,3 mg/24 h
Rivastigmine 3M
Rivastigmin 3M
Rivastigmine 3M Health Care Ltd is a ‘generic medicine’.
Rivastigmine 3M Health Care Ltd je „generički lijek”.
Rivastigmine 3M Health Care Ltd is used to treat patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Rivastigmine 3M Health Care Ltd koristi se za liječenje bolesnika oboljelih od blage do umjereno teške Alzheimerove demencije, progresivnog poremećaja mozga koji postepeno utječe na pamćenje. intelektualnu sposobnost i ponašanje.
Rivastigmine 3M Health Care Ltd.
Rivastigmin 3M Health Care Ltd.
Rivastigmine 3M Health Care Ltd. is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Rivastigmin 3M Health Care Ltd. se primjenjuje u liječenju poremećaja pamćenja u odraslih bolesnika s blagom do umjerenom Alzheimerovom demencijom, progresivnim poremećajem mozga koji postupno utječe na pamćenje, intelektualne sposobnosti i ponašanje.
Rivastigmine 3M Health Care Ltd. might interfere with anticholinergic medicines some of which are medicines used to relieve stomach cramps or spasms (e.g. dicyclomine), to treat Parkinson’s disease (e.g. amantadine) or to prevent motion sickness (e.g. diphenhydramine, scopolamine or meclizine).
Rivastigmin 3M Health Care Ltd. može utjecati na antikolinergičke lijekove (lijekovi koji se koriste za ublažavanje grčeva ili spazama u želucu (npr. diciklomin), za liječenje Parkinsonove bolesti (npr. amantadin) ili za sprječavanje putne mučnine (npr. difenhidramin, skopolamin ili meklizin).
Rivastigmine 3M Health Care Ltd. patches are transparent to translucent, plastic patches that stick to the skin.
Rivastigmin 3M Health Care Ltd. flasteri su prozirni do zamućeni, plastični flasteri koji se lijepe na kožu.
Rivastigmine 3M Health Care Ltd. should not be used during pregnancy unless clearly necessary.
Rivastigmin 3M Health Care Ltd. treba izbjegavati tijekom trudnoće, osim ako njegova primjena nije doista nužna.
Rivastigmine 4.6 mg/24 h
Rivastigmin 4,6 mg/24 h
Rivastigmine 6-12 mg N=379
Rivastigmin 6-12 mg
Rivastigmine 6-12 mg N=379
Rivastigmin 6-12 mg N=473
Rivastigmine 6-12 mg N=473
Rivastigmin 6-12 mg
Rivastigmine 6–12 mg N=379
Rivastigmin 6-12 mg N=379
Rivastigmine 6–12 mg N=379
Rivastigmin 6–12 mg N=379
Rivastigmine 6–12 mg N=473
Rivastigmin 6-12 mg N=473
Rivastigmine 6–12 mg N=473
Rivastigmin 6–12 mg N=473
Rivastigmine 9.5 mg/24 h
Rivastigmin 9,5 mg/24 h
Rivastigmine Actavis
Rivastigmin Actavis
Rivastigmine Actavis 1.5 mg
Rivastigmin Actavis 1,5 mg
Rivastigmine Actavis 1.5 mg capsules rivastigmine
Rivastigmin Actavis 1,5 mg kapsule rivastigmin
Rivastigmine Actavis 1.5 mg hard capsules rivastigmine
Rivastigmin Actavis 1,5 mg tvrde kapsule rivastigmin
Rivastigmine Actavis 1.5 mg hard capsules, which contain off-white to slightly yellow powder, have a yellow cap and yellow body, with red imprint “RIV 1.5mg” on body.
Rivastigmin Actavis 1,5 mg tvrde kapsule, sadrže bjelkasti do blago žuti prašak, imaju žutu kapicu i žuto tijelo, s crvenom oznakom „RIV 1.5mg“ na tijelu kapsule.
Rivastigmine Actavis 3 mg
Rivastigmin Actavis 3 mg
Rivastigmine Actavis 3 mg capsules rivastigmine
Rivastigmin Actavis 3 mg kapsule rivastigmin
Rivastigmine Actavis 3 mg hard capsules rivastigmine
Rivastigmin Actavis 3 mg tvrde kapsule rivastigmin
Rivastigmine Actavis 3 mg hard capsules, which contain off-white to slightly yellow powder, have an orange cap and orange body, with red imprint “RIV 3mg” on body.
Rivastigmin Actavis 3 mg tvrde kapsule, sadrže bjelkasti do blago žuti prašak, imaju narančastu kapicu i narančasto tijelo, s crvenom oznakom „RIV 3mg“ na tijelu kapsule.
Rivastigmine Actavis 3 mg, 4.5 mg and 6 mg hard capsules: Red iron oxide (E172), titanium dioxide (E171), yellow iron oxide (E172) and gelatine.
Rivastigmine Actavis 3 mg, 4,5 mg i 6 mg tvrde kapsule: crveni željezov oksid (E172), titanijev dioksid (E171), žuti željezov oksid (E172) i želatina
Rivastigmine Actavis 4.5 mg
Rivastigmin Actavis 4,5 mg
Rivastigmine Actavis 4.5 mg capsules rivastigmine
Rivastigmin Actavis 4,5 mg kapsule rivastigmin
Rivastigmine Actavis 4.5 mg hard capsules rivastigmine
Rivastigmin Actavis 4,5 mg tvrde kapsule rivastigmin
Rivastigmine Actavis 4.5 mg hard capsules, which contain off-white to slightly yellow powder, have a red cap and red body, with white imprint “RIV 4.5mg” on body.
Rivastigmin Actavis 4,5 mg tvrde kapsule, sadrže bjelkasti do blago žuti prašak, imaju crvenu kapicu i crveno tijelo, s bijelom oznakom „RIV 4.5mg“ na tijelu kapsule.
Rivastigmine Actavis 6 mg
Rivastigmin Actavis 6 mg
Rivastigmine Actavis 6 mg capsules rivastigmine
Rivastigmin Actavis 6 mg kapsule rivastigmin
Rivastigmine Actavis 6 mg hard capsules rivastigmine
Rivastigmin Actavis 6 mg tvrde kapsule rivastigmin